Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
60628-96-8
Molecular formula
C22H18N2
Molecular weight
310.4 g/mol
Drug class
Imidazole antifungal agent
Mechanism of action
Inhibits fungal ergosterol biosynthesis, principally through inhibition of lanosterol 14α-demethylase and additional effects on sterol pathways, disrupting fungal cell-membrane structure and function.
Indications / reported uses
Topical treatment of superficial dermatophyte and yeast infections of the skin, including tinea pedis and other cutaneous mycoses, according to the locally authorised formulation
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Bifonazole PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bifonazole Permitted Daily Exposure (PDE) report (the Bifonazole PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bifonazole Occupational Exposure Limit (OEL) report (the Bifonazole OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.